SUZHOU, China, July 9, 2018 /PRNewswire/ -- Adagene, Inc., an innovative antibody engineering and discovery company, hasreceived notification from the FDA to proceed on its Investigational New Drug (IND) application to study its lead product (ADG-106) in patients with advanced solid tumors and non-Hodgkin lymphoma.
CD137 or 4-1BB, a member of the tumor necrosis
"ADG-106 is targeting a different epitope of CD137 compared with the other two therapeutic antibodies against this target in early clinical trials", said Peter Luo, CEO and Co-Founder of Adagene. "Our proprietary Dynamic Precision Library was able to generate an antibody that targets a unique epitope with cross-reactivity, enabling robust translational studies in both efficacy and safety. ADG-106 is the only monoclonal antibody against this target that has demonstrated potent single agent efficacy in multiple tumor models with intact immune system and work in synergy with other therapeutics, while maintaining an excellent safety profile at extremely high dose. We look forward to starting our clinical trial in the United States soon."
Adagene (Suzhou, China and San Francisco, California) is an innovative antibody engineering and discovery company, by utilizing its proprietary Dynamic Precision Library Platform (DPL), Adagene is showcasing its exceptional antibody engineering capabilities by building franchises of products that are second and third-generation antibodies.
The company's management team is composed of industry veterans with proven track record in therapeutic antibody R&D. Adagene is backed by top notch global venture funds such as F-Prime Capital Partners, Eight Roads Ventures, 6 Dimensions Capital, GP Healthcare Capital, New World TMT Ltd and Sequoia China. The company has raised over $85 million through its series A to C financing.
View original content:http://www.prnewswire.com/news-releases/us-fda-approves-adagene-io-program-ind-for-solid-tumor-and-non-hodgkin-lympoma-ph1-trial-300677554.html
Subscribe to our Free Newsletters!
Necrotizing fasciitis is a rare life threatening bacterial infection of the tissue below the skin ...
Menstruation or period is the discharge of blood and mucus called menses from the uterus via the ...
Chronic dieting is associated with eating disorders that mainly include unhealthy eating practices ...View All